Previous close | 0.0480 |
Open | 0.0490 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0480 - 0.0490 |
52-week range | 0.0390 - 0.1900 |
Volume | |
Avg. volume | 11,557,600 |
Market cap | N/A |
Beta (5Y monthly) | 3.34 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0050 |
Earnings date | 30 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
It might be of some concern to shareholders to see the Imugene Limited ( ASX:IMU ) share price down 19% in the last...
10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy)1Cohort B: 4 patients were treated with azer-cel, lymphodepletion (chemotherapy)1, and interleukin 2 (IL-2) 3 complete responses - The first 2 patients treated in Cohort B achieved a complete response (CR) and 1 patient treated in Cohort A achieved a CRDurability of CRs in Cohort B; >120 days and >90 days
Imugene Limited ( ASX:IMU ) is possibly approaching a major achievement in its business, so we would like to shine some...